Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

Nature Medicine

Volumn 13, Issue 7, 2007, Pages 857-861

  Roberts, Jeffrey N ^a   Buck, Christopher B ^a   Thompson, Cynthia D ^a   Kines, Rhonda ^a   Bernardo, Marcelino ^b   Choyke, Peter L ^a   Lowy, Douglas R ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; MICROBICIDE; NONOXINOL 9; SPERMICIDAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDYLOMA; CONTROLLED STUDY; FEMALE; GENETIC TRANSDUCTION; GENITAL TRACT INFECTION; HISTOLOGY; HUMAN PAPILLOMAVIRUS TYPE 16; IMAGING; INFECTION SENSITIVITY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VIRUS TRANSMISSION; WART VIRUS;

ANIMALS; CAPSID; CARRAGEENAN; FEMALE; HUMAN PAPILLOMAVIRUS 16; MICE; MUCOUS MEMBRANE; NONOXYNOL; PAPILLOMAVIRUS INFECTIONS; SPERMATOCIDAL AGENTS; VAGINA;

ANIMALIA; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 34447122482     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1598     Document Type: Article

References (26)

1. Trottier, H. & Franco, E.L. The epidemiology of genital human papillomavirus infection. Vaccine (2005).
2. Lowy, D.R. & Schiller, J.T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116, 1167-1173 (2006).
3. Campo, M.S. Animal models of papillomavirus pathogenesis. Virus Res. 89, 249-261 (2002).
4. Buck, C.B., Pastrana, D.V., Lowy, D.R. & Schiller, J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78, 751-757 (2004).
5. Buck, C.B., Thompson, C.D., Pang, Y.Y., Lowy, D.R. & Schiller, J.T. Maturation of papillomavirus capsids. J. Virol. 79, 2839-2846 (2005).
6. Richards, R.M., Lowy, D.R., Schiller, J.T. & Day, P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 103, 1522-1527 (2006).
7. Pastrana, D.V. et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205-216 (2004).
8. Pyeon, D., Lambert, P.F. & Ahlquist, P. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. USA 102, 9311-9316 (2005).
9. Buck, C.B. et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2, e69 (2006).
10. Pastrana, D.V. et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337, 365-372 (2005).
11. Reuter, J.D., Gomez, D., Brandsma, J.L., Rose, J.K. & Roberts, A. Optimization of cottontail rabbit papilloma virus challenge technique. J. Virol. Methods 98, 127-134 (2001).
12. Shaner, N.C. et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat. Biotechnol. 22, 1567-1572 (2004).
13. Roberts, J.N. et al. Infection of murine vaginal or endocervical mucosa with human papillomavirus pseudovirions. Nat. Protoc. published online July 2007 (doi:10.1038/nprot.2007.235).
14. Gimenez-Conti, I.B. et al. Expression of keratins in mouse vaginal epithelium. Differentiation 56, 143-151 (1994).
15. Roden, R.B. et al. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J. Virol. 75, 10493-10497 (2001).
16. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D.R. & Schiller, J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89, 12180-12184 (1992).
17. Koutsky, L.A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002).
18. Harper, D.M. et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757-1765 (2004).
19. Niruthisard, S., Roddy, R.E. & Chutivongse, S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm. Dis. 18, 176-179 (1991).
20. Patton, D.L., Kidder, G.G., Sweeney, Y.C., Rabe, L.K. & Hillier, S.L. Effects of multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal epithelium in the pigtailed macaque (Macaca nemestrina). Am. J. Obstet. Gynecol. 180, 1080-1087 (1999).
21. Culp, T.D., Budgeon, L.R., Marinkovich, M.P., Meneguzzi, G. & Christensen, N.D. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J. Virol. 80, 8940-8950 (2006).
22. Wilkinson, D., Tholandi, M., Ramjee, G. & Rutherford, G.W. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect. Dis. 2, 613-617 (2002).
23. Hermonat, P.L., Daniel, R.W. & Shah, K.V. The spermicide nonoxynol-9 does not inactivate papillomavirus. Sex. Transm. Dis. 19, 203-205 (1992).
24. Coggins, C. et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex. Transm. Infect. 76, 480-483 (2000).
25. Spieler, R. Seaweed compound's anti-HIV efficacy will be tested in southern Africa. Lancet 359, 1675 (2002).
26. Maguire, R.A., Zacharopoulos, V.R. & Phillips, D.M. Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Sex. Transm. Dis. 25, 494-500 (1998).